Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers

Documenti analoghi

• Soluble epoxide hydrolase (sEH) is a novel anti‐inflammatory target and a first‐in‐class, picomolar sEH inhibitor (EC5026) improves cognition in a mouse model of Alzheimer’s disease
  di: Yichen Li, et al.
  Pubblicazione: (2024)
• Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study
  di: Yuhao Wang, et al.
  Pubblicazione: (2025)
• A randomized, double‐blind, placebo‐controlled, multiple ascending dose study to evaluate the efficacy, pharmacokinetics, and safety of ABBV‐916 in adults with early Alzheimer’s disease
  di: Shau Yu Lynch, et al.
  Pubblicazione: (2025)
• Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies
  di: Yuji Kumagai, et al.
  Pubblicazione: (2025)
• Randomized, single‐centre, double‐blinded repeated dose investigation of safety and tolerability of ocular administrations of a novel silica eye drop product in healthy volunteers
  di: Aleksandra Poluianova, et al.
  Pubblicazione: (2026)